Graduatoria Bando Giovani Ricercatori Alessandro Liberati 2013

Size: px
Start display at page:

Download "Graduatoria Bando Giovani Ricercatori Alessandro Liberati 2013"

Transcription

1 Programma di ricerca Regione-Università Graduatoria Bando Giovani Ricercatori Alessandro Liberati 2013 PPOSSIIZZIIONEE CCODIICCEE CCOGNOMEE NOMEE EENTTEE ANALYSIS OF T CELL POPULATION TO OBTAIN A LO MONACO Andrea AO-U di Ferrara Viral and autoimmune pathologies BIOLOGIC FREE-DRUG REMISSION IN PATIENTS AFFECTED BY RHEUMATOID ARTHRITIS IN REMISSION PHASE INDUCED BY TNF-BLOCKER THERAPY 93, ZANONI Lucia AO-U 18F-FACBC PET/CT FOR STAGING HIGH RISK PROSTATE CANCER 91,111 MAGNETIC RESONANCE GUIDED BAZZOCCHI Alberto Oncology HIGH INTENSITY FOCUSED ULTRASOUND TREATMENT OF BONE METASTASES: PAIN PALLIATION, AND LOCAL TUMOR CONTROL? 91, GRAZIANO Angela AO-U di Ferrara SILENT INTRACELLULAR INFECTIONS AND EARLY PREGNANCY LOSS 90,000

2 INVESTIGATION OF HUMAN EPILEPTIC NETWORKS BY FMRI VAUDANO Anna-Elisabetta AO-U di Modena Neuroscience BASED EFFECTIVE CONNECTIVITY: A NEW APPROACH TO IDENTIFY THE NEURONAL DRIVERS OF THE 90,000 PATHOLOGICAL ACTIVITY IN SURGICALLY REMEDIABLE EPILEPSIES LO MONTE Giuseppe AO-U di Ferrara PROGNOSTIC MARKERS IN WOMEN WITH PRIMARY UNEXPLAINED INFERTILITY. 88,889 WHOLE-TANSCRIPTOME PAIRED-END SEQUENCING IN VECCHIARELLI Silvia AO-U Oncology PANCREATIC CANCER AND PRECURSOR LESIONS: FROM 87,778 EARLY DETECTION TO THERAPEUTIC IMPLICATIONS DIAGNOSTIC ACCURACY AND PEDRINI Elena COST-EFFECTIVENESS OF NEXT GENERATION SEQUENCING (NGS) STRATEGIES IN THE GENETIC TESTING OF RARE 87,778 ORTHOPAEDIC DISEASES PALMERINI Emanuela Oncology ASSESSMENT OF MGMT PROMOTER METHYLATION AND CLINICAL BENEFIT FROM TEMOZOLOMIDE-BASED THERAPY IN EWING SARCOMA 86,667 PATIENTS 2

3 EFFICACY OF A NOVEL SIMPLIFIED, MINIMALLY FARINA Roberto AO-U di Ferrara INVASIVE PROCEDURE FOR SINUS FLOOR ELEVATION IN THE ATROPHIC POSTERIOR MAXILLA: A MULTICENTER, RANDOMIZED STUDY. 86, MARTORANA Davide AO-U di Parma Viral and autoimmune pathologies TAILORING RITUXIMAB TREATMENT IN ANCA- ASSOCIATED VASCULITIS: A GENETIC AND IMMUNOLOGICAL APPROACH 85,556 ROLE OF DIAPHRAGMATIC FANTINI Riccardo AO-U di Modena ULTRASOUND IN PROGNOSIS AND IN RESPIRATORY EVALUATION IN PATIENT WITH AMYOTROPHIC LATERAL SCLEROSIS (ECODISLA) 85,556 REGIONAL REGISTRY-BASED ASSIRELLI Elisa BIOBANK DEVELOPMENT AND PHARMACOGENETIC ANALYSIS: SYNERGISTIC STRATEGIES DRIVING TOWARDS PERSONALIZED MEDICINE IN RHEUMATOID ARTHRITIS MANAGEMENT 85,556 RADIODYNAMIC THERAPY: A AVNET Sofia Oncology NOVEL APPROACH FOR THE TREATMENT OF PAIN IN PATIENTS WITH BONE METASTASES 84,444 3

4 NEGRI Francesca AO-U di Parma Oncology VALIDATION OF NOTCH AND DLL4 EXPRESSION AS INDEPENDENT PREDICTORS OF CLINICAL OUTCOME IN COLORECTAL CANCER PATIENTS TREATED WITH BEVACIZUMAB: A PROSPECTIVE COHORT STUDY 84,444 MELANOPSIN RETINAL LA MORGIA Chiara delle Scienze Neurologiche di Bologna Neuroscience GANGLION CELLS AND CIRCADIAN PHOTOENTRAINMENT IN ALZHEIMER'S DISEASE, DOWN SYNDROME AND AGING. 84,444 INDUCTION OF A SUSPENDED ZUCCHELLI Mino delle Scienze Neurologiche di Bologna Neuroscience ANIMATION STATE BY INHIBITION OF NEURONS OF THE CENTRAL NERVOUS PATHWAY FOR THERMOREGULATORY COLD DEFENSE IN PIGS 84, MANFERDINI Cristina BIOSAFETY OF MESENCHYMAL STEM CELLS FOR CLINICAL USE: IMPROVEMENT OF GENETIC STABILITY ASSESSMENT BY NEXT GENERATION SEQUENCING TOOLS. 83,333 HIGH-THROUGHPUT PIPPUCCI Tommaso AO-U SEQUENCING IN EPILEPSY GENETICS: IMPROVEMENT OF DIAGNOSTIC SERVICES AND NOVEL GENOTYPE-PHENOTYPE CORRELATIONS 83,333 4

5 BEDSIDE EVALUATION OF SPADARO Savino AO-U di Ferrara RESPIRATORY MUSCLE DISFUNCTION DURING MECHANICAL VENTILATION IN CRITICAL PATIENTS. 83,333 EXPLOITATION OF EPIGENETICS CANTONI Silvia AO-U Cardiovascular TO DECIPHER AND MODULATE CELL GROWTH, MIGRATION AND DIFFERENTIATION IN PULMONARY ARTERIAL HYPERTENSION 82,222 IDENTIFICATION OF TUMOR KURELAC Ivana AO-U Oncology SUBSETS WITH INCREASED MITOCHONDRIAL CAPACITY AND IMPLEMENTATION OF METHODS FOR THEIR DETECTION IN MELANOMA 82, MONTALTI Maurizio Neuroscience METAL ON METAL HIP PROSTHESIS: COBALT-INDUCED NEUROTOXICITY. 82,222 WIDE-GENOME HIGH PANTALEO Maria Abbondanza AO-U Oncology THROUGHPUT SEQUENCING OF LIPOSARCOMA FOR OPTIMIZING PROGNOSIS, FOLLOW-UP AND TREATMENT 82,222 MONOGENIC DIABETES: NOVEL MARASCO Elena AO-U EXTENDED GENETIC TEST FOR IMPROVING MOLECULAR DIAGNOSIS AND TAILORING TREATMENT 81,667 5

6 DETECTION OF HUMAN PAPILLOMAVIRUS AS A VIDONE Michele AO-U Oncology DIAGNOSTIC AND PROGNOSTIC TOOL IN GLIOBLASTOMA MULTIFORME AND LOWER- 81,111 GRADE GLIOMAS GAROFALO Cecilia Oncology IR-A AS NEW PLAYER IN SARCOMA MALIGNANCY 80, GAMBARI Laura HYDROGEN SULFIDE AS A NOVEL MARKER OF BONE METABOLISM IN OSTEOPOROTIC PATIENTS 80,000 CD8 CELL FUNCTION AND T LACCABUE Diletta AO-U di Parma Viral and autoimmune pathologies CELL RECEPTOR SIGNALING AS PREDICTORS OF ANTI-VIRAL T- CELL RESCUE AND EARLY NUCLEOS(T)IDE ANALOGUE (NUC) SUSPENSION IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS. 80, MELLONE Sabato AO-U di Modena A NOVEL DIAGNOSTIC TOOL FOR PERSONALIZED SENSOR-BASED FALL RISK ASSESSMENT 78,889 TRANSLATING NOVEL TREATMENTS FOR GRISENDI Giulia AO-U di Modena Oncology OSTEOSARCOMA FROM THE UNDERSTANDING OF TUMOR - STROMA INTERACTIONS. (TRATOS PROJECT) 78,889 6

7 CIRCULATING PROGENITOR GRAIANI Gallia AO-U di Parma Cardiovascular CELLS DYSFUNCTION AS A PATHOGENETIC AND THERAPEUTIC TARGET FOR ANTI-CANCER DRUGS INDUCED CARDIOVASCULAR DISEASES. 78,889 IMMUNOLOGICAL AND ANTI CONTOLI Marco AO-U di Ferrara Viral and autoimmune pathologies VIRAL IMMUNE RESPONSES OF THE FREQUENT-EXACERBATION PHENOTYPE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 78, ZAMAGNI Elena AO-U Oncology STANDARDIZATION OF CRITERIA FOR PET/CT IMAGING EVALUATION IN PATIENTS WITH MULTIPLE MYELOMA TREATED UP- FRONT WITH NOVEL AGENTS AND CORRELATION BETWEEN PET/CT AND OTHER PROGNOSTIC FACTORS 78,889 EMERGING NEUROINVASIVE ROSSINI Giada AO-U Viral and autoimmune pathologies INFECTIONS IN ITALY: FOCUS ON WEST NILE VIRUS PATHOGENESIS, EVOLUTION AND DIAGNOSIS 78, GALLETTI Silvia AO-U Cardiovascular MYOCARDIAL DYSFUNCTION AND LONG-TERM OUTCOME IN ASPHYXIATED INFANTS 78,333 7

8 IDENTIFICATION OF RISK PROFILES IN THE ITALIAN PONTI Francesca Oncology POPULATION FOR DEVELOPMENT OF PREVENTION INTERVENTIONS IN LI FRAUMENI SYNDROME AND RELATED PHENOTYPES 77,778 IDENTIFICATION OF MUCORALES-SPECIFIC IMMUNOLOGICAL MARKERS FOR RIVA Giovanni AO-U di Modena THE DIAGNOSIS OF INVASIVE MUCORMYCOSIS (IM) AND FOR THE ASSESSMENT OF MUCORALES INFECTION PREVALENCE IN IMMUNOCOMPROMISED PATIENTS. 77, MAFFEI Rosanna AO-U di Modena Oncology ENDOTHELIN-1 SIGNALING PATHWAY IN CHRONIC LYMPHOCYTIC LEUKEMIA: PROGNOSTIC, FUNCTIONAL AND THERAPEUTIC IMPLICATIONS 77, GASPARRE Giuseppe AO-U Oncology MITOCHONDRIAL GENOTYPING: A NEW TOOL FOR SYNCHRONY CANCER DETECTION 77,778 8

9 C SUBUNIT OF THE FO ATP- SYNTHASE AND OUTCOME IN CAMPO Gianluca Calogero AO-U di Ferrara Cardiovascular PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING 77,778 PRIMARY PERCUTANEOUS CORONARY INTERVENTION BARILI Valeria AO-U di Parma Viral and autoimmune pathologies GENE AND MIRNA PROFILES AS EARLY PREDICTORS OF ANTI- HBV CONTROL RECONSTITUTION AND SAFE SHORTENING OF NUCLEOS(T)IDE ANALOG (NUC) THERAPY IN CHRONIC HBV 77,778 PATIENTS AQUILANO Adelia AO-U DISEASE-TARGETED SEQUENCING: A NEW APPROACH FOR IMPROVING THE MOLECULAR DIAGNOSIS OF POLYCYSTIC KIDNEY DISEASE 76,667 WIDE MOLECULAR CHARACTERIZATION OF THE PARAGANGLIOMAS (PGLS) AND NANNINI Margherita AO-U Oncology THE PHEOCROMOCITOMAS (PCCS) WITH HIGH- THROUGHPUT TECHNOLOGIES: 76,667 IDENTIFICATION OF PROGNOSTIC FACTORS AND NOVEL THERAPEUTIC TARGETS 9

10 DEVELOPMENT OF A DIGITAL IMAGE ANALYSIS APPROACH FOR IMPROVEMENTS IN PARRILLI Annapaola MUSCULOSKELETAL DISEASE DIAGNOSTIC: QUANTITATIVE ELASTOSONOGRAPHY AND ITS VALIDATION WITH HISTOLOGY AND 3D MICROCT EVALUATIONS 76,667 IDENTIFICATION OF NEW DRUG TARGETS IN MULTIPLE STORTI Paola AO-U di Parma Oncology MYELOMA PATIENTS: A NEW STRATEGY FOR AN HIGH- THROUGHPUT SCREENING (HTS) WITH SHRNA LENTIVIRUS AND IN VIVO VALIDATION. 76,667 THE USE OF DYNAMIC RADIOSTEREOMETRIC ANALYSIS BRUNI Danilo TO EVALUATE KINEMATICS AND BIOMECHANICS OF TOTAL KNEE ARTHROPLASTY IN REAL-LIFE CONDITIONS: WEIGHT-BEARING MOTION WITH ACTIVE MUSCLE CONTRACTION. 76,667 10

11 URICEMIA AS AN EARLY AND INEXPENSIVE MARKER OF VASCULAR DAMAGE: ITS CICERO Arrigo Francesco Giuseppe AO-U Cardiovascular RELATIONSHIP WITH INFLAMMATORY AND METABOLIC PARAMETERS IN PATIENTS WITH 76,667 DIFFERENT DEGREES OF CHRONIC KIDNEY DISEASE AND CONTROLS PLATELET PKC EPSILON NOTARANGELO Maria Francesca AO-U di Parma Cardiovascular EXPRESSION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: CAN WE PRE-DATE THROMBOTIC EVENTS? 75, GAMAL MOHAMED ABDELALL Nesrine AO-U Viral and autoimmune pathologies PREVALENCE OF HEPATITIS B VIRUS INFECTION AMONG PATIENTS WITH DIFFERENT RHEUMATIC DISEASES 75, FILARDO Giuseppe PRP: A NEW BIOLOGICAL APPROACH FOR TENDON TREATMENT. FROM IN VITRO STUDY TO CLINICAL APPLICATION OF PLATELET- DERIVED GROWTH FACTORS 75,556 TARGETED AT TENDON REGENERATION CANELLA Valentina MICRORNA "SIGNATURES" TO DEFINE PROGRESSION AND THERAPY OF OA 75,556 11

12 COMBINED PREDNISONE AND PALMISANO Alessandra AO-U di Parma Viral and autoimmune pathologies MYCOPHENOLATE MOFETIL FOR THE TREATMENT OF IDIOPATHIC RETROPERITONEAL FIBROSIS: A MULTICENTER OPEN-LABEL RANDOMISED TRIAL 75,556 IMPLEMENTING DIFFERENTIAL CALANDRA BONAURA Giovanna delle Scienze Neurologiche di Bologna Neuroscience DIAGNOSIS BETWEEN PARKINSON'S DISEASE AND MULTIPLE SYSTEM ATROPHY BY MEANS OF A STANDARDIZED SET OF CARDIOVASCULAR REFLEX TESTS 75, PORTINARI Mattia AO-U di Ferrara Oncology THE A3 ADENOSINE RECEPTOR: POTENTIAL TARGET FOR DIAGNOSIS, PROGNOSIS AND THERAPY OF CANCER 75, BUTI Sebastiano AO-U di Parma Oncology A NEW MODFIEDW MODIFIED SCHEDULE OF SUNITINIB FOR FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA: A RANDOMIZED PHASE II STUDY 75, CALLEGARI Elisa AO-U di Ferrara Oncology MICRORNA-BASED APPROACHES FOR HEPATIC TUMOR PROPHYLAXIS AND THERAPY 74,444 12

13 FERRACIN Manuela AO-U di Ferrara Oncology CIRCULATING MICRORNAS FOR THE EARLY DIAGNOSIS OF RECURRENCES OF COMMON CARCINOMAS 74,444 IMPROVING SELECTIVITY OF CANCER THERAPY: STUDY OF CHIARINI Francesca Oncology SIGNALING PATHWAYS INVOLVED IN MODULATING SENSITIVITY TO NELARABINE IN PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T- ALL) 74,444 AN AUTOLOGOUS AND ALLOGENIC COMPOSITE NERVE GRAFT VERSUS PURE BORIANI Filippo AUTOLOGOUS AND PURE ALLOGENIC GRAFTING ALONE: AN ORIGINAL COMPARATIVE STUDY TO EVALUATE AN INNOVATIVE NERVE DECELLULARIZATION TECHNIQUE. 74,444 ATTENTIONAL DISORDERS AND DEFAULT MODE NETWORK IN FILIPPINI Melissa delle Scienze Neurologiche di Bologna Neuroscience CHILDREN WITH IDIOPATHIC FOCAL AND GENERALIZED EPILEPSY: FINGERPRINTS OF BRAIN ACTIVATION AND EARLY NEUROPSYCHOLOGICAL INTERVENTION 73,333 13

14 COMPARATIVE IN VITRO CAVALLO Carola EVALUATION OF AUTOLOGOUS AND ALLOGENIC PLATELET RICH PLASMA AS AUGMENTATION STRATEGY FOR CARTILAGE TISSUE ENGINEERING. 73,333 EPIDEMIOLOGICAL SURVEILLANCE OF RAVAIOLI Stefano METHICILLIN-RESISTANT AND METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS 73,333 FROM IMPLANT-ASSOCIATED INFECTIONS EFFECTS OF HYPERBARIC BEVONI Roberto OXYGEN THERAPY (HBOT) ON NEW BONE FORMATION OBTAINED BY DISTRACTION 73,333 OSTEOGENESIS IMPACT OF TIMELY TREATMENT OF MALNUTRITION ON HEALTHCARE COST OF PATIENTS AGOSTINI Federica AO-U Rehabilitation HOSPITALIZED IN INTERNAL MEDICINE UNIT: ASSESSMENT 73,333 OF THE EFFICACY OF A STANDARDIZED NUTRITIONAL INTERVENTION VARGIOLU Manuela AO-U Oncology PHOSPHODIESTERASE (PDE) INHIBITORS FOR THYROID CANCER THERAPY (POINT) 72,222 14

15 NICODEMO Marianna delle Scienze Neurologiche di Bologna Neuroscience CORRELATION OF ULTRASONOGRAPHIC, ELECTROPHYSIOLOGICAL AND CLINICAL FINDINGS: A PROSPECTIVE STUDY IN IMMUNE-MEDIATED NEUROPATHIES 72,222 EXERCISE AND DIABETES: A RANDOMIZED STUDY HADDOUB Silvia AO-U di Parma Rehabilitation EVALUATING METABOLIC AND FUNCTIONAL EFFECTS OF A PROGRAM OF PHYSICAL 72,222 ACTIVITY IN ELDERLY DIABETIC PATIENTS PREDICTION OF CONVERSION TONDELLI Manuela AO-U di Modena Neuroscience FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER'S DISEASE USING A 72,222 MULTIFACTORIAL INDEX LOPOMO Nicola Francesco NANOSTRUCTURED BIOMIMETIC HYDROXYAPATITE COATINGS FOR ANTI-OSTEOPOROTIC PEEK IMPLANTS 71,111 PATELLAR MALTRACKING AND PATELLA Silvio PATELLO-FEMORAL MALALIGNMENT: A DYNAMIC IN VIVO BIOMECHANICAL RSA STUDY AND ITS CLINICAL 71,111 CORRELATION AFTER CORRECTIVE SURGERY 15

16 DECISION MAKING FOR SESTITO Mariateresa AO-U di Modena Neuroscience PRIMARY AND SECONDARY REWARDS IN PATIENTS WITH ANTERIOR AND POSTERIOR ORBITOFRONTAL BRAIN DAMAGE 71, MAGINI Pamela AO-U Neuroscience INVESTIGATING THE ROLE OF NOTCH3 AND HTRA1 LOSS OF FUNCTION MUTATIONS IN THE PATHOGENESIS OF SPORADIC LACUNAR STROKE. 71, MICHELACCI Francesca Oncology DNA REPAIR SYSTEM AND CISPLATIN RESISTANCE IN OSTEOGENIC BONE TUMOURS: VALIDATION OF MOLECULAR TARGETS AND PRECLINICAL STUDY OF DNA REPAIR INHIBITORS. 71, BRODOSI Lucia AO-U A PHASE II STUDY OF AUTOLOGOUS BONE MARROW - DERIVED STEM CELL TRANSPLANTATION FOR THE TREATMENT OF CHRONIC END STAGE LIVER DISEASE 71,111 16

17 FINI Nicola AO-U di Modena Neuroscience A STUDY OF DISEASE BIOMARKERS AND PATHOGENIC MECHANISMS FROM THE AMYOTROPHIC LATERAL SCLEROSIS EMILIA- ROMAGNA REGIONAL REGISTRY AND BIOBANK 71,111 CIRCULATING EXTRACELLULAR TUROLA Elena AO-U di Modena VESICLES (EMVS) AS NOVEL BIOMARKER FO THE EARLY DETECTION OF HEPATOCELLULAR CARCINOMA (HCC) 70,000 DECIPHERING MOLECULAR TIRAFERRI Ilaria AO-U di Modena Neuroscience GENETIC MECHANISMS IN CLUSTER HEADACHE: A GENOME WIDE ASSOCIATION AND COPY-NUMBER VARIATION STUDY 70,000 HOMING OF ENDOGENOUS MESENCHYMAL STEM CELLS AND PANSERI Silvia CONTROLLED BISPHOSPHONATE DRUG DELIVERY VIA HYDROXYAPATITE-BASED BIOMATERIAL AS MULTIPLE INNOVATIVE APPROACH FOR OSTEOPOROSIS. 70,000 17

18 EPIGENETIC IN MEDICATION FAVONI Valentina delle Scienze Neurologiche di Bologna Neuroscience OVERUSE HEADACHE -- FROM MOLECULAR MECHANISM TO CLINICAL ISSUES IN THE FIELD OF REFRACTORY CHRONIC DAILY HEADACHES. 70,000 IDENTIFICATION OF A PREDICTIVE ALGORITHM OF GIACUZZO Sarah AO-U di Ferrara Viral and autoimmune pathologies RESPONSE TO METHOTREXATE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS CANDIDATE TO FIRST-LINE TREATMENT USING A DATA- MINING APPROACH 70, BIAGIONI Emanuela AO-U di Modena ENDOTOXIN BLOOD ABSORPTION IN CANDIDATE TO LIVER TRANSPLANTATION WITH SEPTIC SHOCK 68,889 IDENTIFICATION OF P53- RELATED SELECTION CRITERIA GUERZONI Clara Oncology FOR A COST-SAVING AND FUNCTIONALE EMPLOYEMENT OF ANTI-CD99 THERAPY OF EWING SARCOMA PEDIATRIC PATIENTS. 68,889 18

19 PINARDI Federica AO-U Neuroscience RANDOMIZED CONTROLLED TRIAL ON COGNITIVE TRAINING IN PATIENTS WITH PARKINSON S DISEASE ON LEVODOPA THERAPY: EFFECTS ON QUALITY OF LIFE. 68, MASSELLI Elena AO-U di Parma Oncology PROTEIN KINASE C EPSILON (PKCE) AS A NOVEL POTENTIAL THERAPEUTIC TARGET IN PRIMARY MYELOFIBROSIS: A PRECLINICAL STUDY 68,889 VALIDATION STUDY OF TISEO Marcello AO-U di Parma Oncology CIRCULATING TUMOR CELLS (CTCS) AND CIRCULATING TUMOR DNA (CTDNA) AS LIQUID BIOPSY TO EVALUATE MECHANISMS OF DRUG- RESISTANCE IN ADVANCED NON- 68,889 SMALL CELL LUNG CANCER (NSCLC) NEXT GENERATION MASETTI Riccardo AO-U Oncology SEQUENCING (NGS)-BASED APPROACH FOR INTEGRATIVE DIAGNOSIS, RISK STRATIFICATION AND NOVEL 68,333 TARGETABLE BIOMARKERS OF PEDIATRIC AND ADULT ACUTE MYELOID LEUKEMIA 19

20 CLINICAL AND IMMUNOLOGICAL MASETTI Marco AO-U PHENOTYPES OF ANTIBODY MEDIATED REJECTION IN HEART TRANSPLANT RECIPIENTS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 67, PERUT Francesca PLATELET-DERIVED EXOSOMES: DEVELOPMENT OF A NEW NANODELIVERY SYSTEM FOR BONE REGENERATION 67,778 MOLECULAR IDENTIFICATION OF BACTERIAL INFECTION FOR BIANCHINI Marcello AO-U di Modena EARLY DIAGNOSIS OF MULTIDRUG RESISTANT STRAINS IN HOSPITALIZED PATIENTS WITH DECOMPENSATED CIRRHOSIS 67,778 CROHN'S DISEASE AND LOMBARDI Giulia AO-U MYCOBACTERIUM AVIUM PARATUBERCULOSIS: COMMENSAL OR EMERGING HUMAN PATHOGEN? 67, ZECCHINI Ramona AO-U di Modena EXTRACELLULAR MICROVESCICLES AS NEW BIOMARKERS FOR PANCREATIC CANCER 67,778 20

21 TSOLAKI Elpiniki AO-U di Ferrara Cardiovascular AN EPIDEMIOLOGICALAND FAMILIAL STUDY IN ABDOMINAL AORTIC ANEURYSM AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: RESEARCH FOR COMMON GENETIC BASES 67,778 TRANSMISSION OF LOCATELLI Chiara AO-U Viral and autoimmune pathologies CYTOMEGALOVIRUS TO PRETERM INFANTS THROUGH BREAST MILK: ROLE OF HUMORAL AND CELL-MEDIATED IMMUNITY 67,222 NATURAL MOLECULES AND BIANCHI Francesca AO-U ADIPOSE-DERIVED STEM CELLS OBTAINED WITH A NEW NON- ENZYMATIC METHOD TO OPTIMIZE CELL THERAPY OF VASCULAR DISEASES 66,667 MULTICENTER QUASI- EXPERIMENTAL STUDY ON SAFETY, EFFICACY AND NUMEROSO Filippo AO-U di Parma Cardiovascular ECONOMIC EFFICIENCY OF A SHORT-TERM DISCHARGE ED PROTOCOL OF INTERMEDIATE- RISK SYNCOPAL PATIENTS AND REASSESSMENT IN A SYNCOPE UNIT 66,667 21

22 GENOME-WIDE AND MIRNA PAZZAGLIA Laura Oncology EXPRESSION IN SYNOVIAL SARCOMA: IDENTIFICATION OF TARGETS FOR COMBINED 66,667 TREATMENTS EPIDEMIOLOGICAL, CLINICAL AND VIROLOGICAL PROFILE OF CONTI Fabio AO-U Viral and autoimmune pathologies ELDERLY WITH CHRONIC HEPATITIS C IN EMILIA- ROMAGNA: FUTURE 66,667 IMPLICATIONS FOR ANTIVIRAL THERAPY ALLOCATION. PRECLINICAL STUDY OF NEW INTEGRIN-SPECIFIC MIGLIARI Silvia AO-U di Parma RADIOPHARMACEUTICALS TARGETING ANGIOGENESIS FOR 66,667 IMAGING AND THERAPY IN NUCLEAR ONCOLOGY ONGOING TRIALS IN MUSCULAR DYSTROPHY: SEARCH FOR FALZARANO Maria Sofia AO-U di Ferrara Neuroscience BIOMARKERS AND NOVEL MOLECULES FOR IMPROVING 65,556 THE EFFICACY OF MOLECULAR THERAPIES TESTING NOX4 EXPRESSION AS AN INNOVATIVE TEST THAT PIERINI Michela WILL ENSURE THAT ONLY ACTIVE MESENCHYMAL STEM CELLS ARE IMPLANTED IN PATIENTS FOR REGENERATIVE 65,556 MEDICINE INTERVENTIONS (NEXT) 22

23 THE ROLE OF MOTOR SBRISCIA FIORETTI Beatrice AO-U di Parma Neuroscience RESONANCE IN DYSLEXIA: A CONTROLLED HIGH DENSITY 65,556 EEG STUDY QUATTRINI Irene Oncology MOLECULAR SIGNATURE IN METASTATIC SARCOMA CELLS: IDENTIFICATION OF KEY BIOMARKERS FOR CLINICAL STRATIFICATION OF SOFT TISSUE SARCOMA PATIENTS. 65,556 MOLECULAR ANALYSIS OF HIV CLò Alberto AO-U Viral and autoimmune pathologies AND ANTIRETROVIRAL DRUG EFFECTS ON BIOLOGY AND DIFFERENTIATION OF HEMATOPOIETIC PROGENITOR CD34+ CELLS (HPCS). 65,556 DEFINING NEW BIOMARKERS OLIVOTTO Eleonora AND INDICATORS FOR DIAGNOSIS AND FOLLOW-UP IN PATIENTS WITH FEMORO- ACETABULAR IMPINGEMENT (FAI) 64,444 CLINICAL, EPIDEMIOLOGICAL, PARRA Alessandro Rehabilitation BIOCHEMICAL AND GENETIC ANALYSES: A ROADMAP FOR HETEROTOPIC OSSIFICATION KNOWLEDGE AND MANAGEMENT. 64,444 23

24 PERSONALISED MODELS FOR A SCHILEO Enrico Oncology COMPUTER ASSISTED EVALUATION OF VERTEBRAL FRACTURE RISK IN TUMOR 64,444 SPINE LESIONS ORTHOPAEDIC AND REHABILITATIVE INTEGRATED COLANGELI Marco Oncology MANAGEMENT IN CHILDREN SURGICALLY TREATED FOR MUSCULO-SKELETAL TUMORS: RECOMMENDATIONS TO 64,444 OPTIMIZE THE FUNCTIONAL OUTCOME HEPATIC INFLAMMATORY BACKGROUND AS MODIFIED BY GITTO Stefano AO-U di Modena REPRODUCTIVE STATUS MAY BE A KEY FACTOR IN DETERMINING THE SEVERITY OF HEPATITIS C 63,333 VIRUS RECURRENCE AFTER LIVER TRANSPLANT MECHANISMS OF ACTION OF CAVAZZUTI Ilaria AO-U di Modena IMMUNOGLOBULIN THERAPY DURING SEPTIC SHOCK: A PILOT STUDY IN CANDIDATES TO LIVER TRANSPLANTATION AND IN 63,333 TRANSPLANTED PATIENTS 24

25 THE ROLE OF PERICELLULAR MATRIX IN HUMAN ANTERIOR CRUCIATE LIGAMENT AND BONDI Alice POSSIBLE ROLE OF BONE MARROW STEM CELLS IN TISSUE ENGINEERING OF ANTERIOR CRUCIATE LIGAMENT. A CLINICAL TRIAL AS CONTROL SERIES. 63,333 EVALUATION OF SORAFENIB GIOVANNINI Catia AO-U Oncology THERAPEUTIC EFFICACY USED FOR HCC THERAPY AND AS ADJUVANT TREATMENT IN THE PREVENTION OF HCC RECURRENCE. 63, BAGLIONI Michele AO-U Oncology NOTCH1 AND NOTCH3 MUTATIONS IN HEPATOCELLULAR CARCINOMA: EVALUATION FOR PRESENT AND FUTURE THERAPIES. 63,333 PHASE I DOSE-ESCALATION AMPOLLINI Luca AO-U di Parma Oncology STUDY OF POLYMERIC FILMS LOADED WITH CISPLATIN FOR MALIGNANT PLEURAL MESOTHELIOMA 63,333 25

26 NEXT GENERATION SEQUENCING TO DETECT DIFFERENCES IN GALLETTI Margherita AO-U Cardiovascular TRANSCRIPTIONAL PROFILE OF PERIPHERAL BLOOD MONONUCLEAR CELLS FROM BMPR2 MUTATION CARRIERS WITH OR WITHOUT PULMONARY ARTERIAL HYPERTENSION 63,333 CONTRIBUTE TO ADVANCED DE PASQUALE Dalila DIAGNOSTIC FOR AN EMERGING IATROGENIC PATHOLOGY: ORTHOPAEDIC PROSTHESIS ASSOCIATED CHROMIUM- COBALT TOXICITY 62,222 ADVANCED IMAGING COMPUTING APPROACH TO BELLETTI Alice AO-U di Parma TUMOR LOCALIZATION IN EARLY-STAGE HEAD&NECK CANCER: IMPACT ON SURGERY AND RADIATION TREATMENT PLANNING 62,222 IDENTIFICATION OF NEW PROGNOSTIC BIOMARKERS IN ONCOLOGY THROUGH PONTI Giovanni AO-U di Modena Oncology PROTEOMIC AND GENOMIC ANALYSIS OF BLOOD SERUM AND FIBROBLAST CULTURES OBTAINED FROM CONSTITUTIONAL MUTATION CARRIER PATIENTS. 62,222 26

27 MOLECULAR BASIS OF NATURAL SOLIERA Angela Rachele AO-U di Modena Oncology KILLER (NK) CELL DYSFUNCTION IN HEPATOCELLULAR CARCINOMA (HCC) 62,222 EFFECTS OF TESTOSTERONE SUPPLEMENTATION ON CLINICAL AND REHABILITATIVE ARTONI Andrea AO-U di Parma Cardiovascular OUTCOMES IN OLDER MEN UNDERGOING ON-PUMP CORONARY ARTERY BYPASS GRAFT SURGERY (CABG): A RANDOMIZED CONTROLLED TRIAL 62, GUIDOTTI Isotta AO-U di Modena Neuroscience EFFICACY OF PHENYTOIN VERSUS PHENOBARBITAL IN THE TREATMENT OF NEONATAL SEIZURES 62,222 PTEN-ASSOCIATED PRADELLA Laura Maria AO-U Oncology CARCINOGENESIS:IMPLICATIONS FOR FEMALE CANCERS' CLASSIFICATION AND TREATMENT. 62,222 27

28 COMPAGNONE Christian Angel AO-U di Parma Neuroscience PROSPECTIVE STUDY OF SEVERE HEAD INJURIED DRIVERS IN FRONTAL CAR COLLISIONS IN THE PROVINCE OF PARMA: IN DEPTH MOTOR-VEHICLE CRASH INVESTIGATION AND COMPUTATIONAL SIMULATION DEVELOPMENT. 62,222 ASSOCIATIONS BETWEEN MOLECULAR MARKERS AND ULAZZI Linda AO-U di Ferrara Oncology CLINICO-PATHOLOGICAL FEATURES IN BRAF-MUTATED COLORECTAL CANCER: IMPLICATIONS FOR PROGNOSIS AND THERAPIES. 60, TOVOLI Francesco AO-U Viral and autoimmune pathologies ROLE OF MICRO-RNAS IN THE DIAGNOSIS AND FOLLOW-UP OF POLYMYALGIA RHEUMATICA 60,000 COMBINING BIODEGRADABLE SARTORI Maria CHAMBERS WITH BIOLOGICAL ACTORS TO ADDRESS CHALLENGES IN MUSCULOSKELETAL DISEASES AND AGING. COM.BB.ACT 60,000 28

29 SANTI Daniele AO-U di Modena Viral and autoimmune pathologies CAN OSTEOPOROSIS BE AN AUTOIMMUNE DISEASE? OCCURRENCE, PATHOGENESIS AND EVOLUTION OF OSTEOPOROSIS IN AUTOIMMUNE THYROIDITIS 60, ZUNTINI Roberta AO-U Oncology IDENTIFICATION OF GENETIC FACTORS INVOLVED IN GASTRIC CANCER 58,889 RECURRENCE PREVENTION OF HEPATOCELLULAR CARCINOMA WITH TRIPLE ANTIVIRAL DI DONATO Roberto AO-U Oncology THERAPY CONTAINING TELAPREVIR IN SUBJECTS WITH HCV-POSITIVE CIRRHOSIS TREATED WITH LIVER RESECTION OR RADIOFREQUENCY ABLATION 58,889 STEM CELLS AND DUCHI Serena Oncology NANOPARTICLES FOR ANTICANCER PHOTOTHERAPY SYSTEM FOR HIGH GRADE OSTEOSARCOMA TREATMENT (SNAPSHOT) 57,778 29

30 MOLECULAR FILONZI Laura AO-U di Parma Cardiovascular CHARACTERIZATION OF CHANNELLOPATIES IN SIDS AND ITS APPLICATION FOR PREVENTION AND DIAGNOSIS 57,778 IMPROVEMENTS IN RISK PATIENTS IDENTIFICATION OF CANDIDATE GIANESINI Sergio AO-U di Ferrara Cardiovascular BIOMARKERS FOR CHRONIC VENOUS DISEASE AND APPLICATION FOR PROGNOSIS 54,444 AND THERAPEUTIC MONITORING CIRILLO Luigi delle Scienze Neurologiche di Bologna INTRACRANIAL ANEURYSM: HAEMODYNAMIC CHARACTERIZATION, RUPTURE PREDICTION AND TREATMENT PLANNING 50,000 30

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of

More information

RICERCA FINALIZZATA+GIOVANI RICERCATORI MALATTIE RARE. Graduatoria e Finanziamento

RICERCA FINALIZZATA+GIOVANI RICERCATORI MALATTIE RARE. Graduatoria e Finanziamento Direzione Generale Ricerca Scientifica e Tecnologica RICERCA FINALIZZATA+GIOVANI RICERCATORI MALATTIE RARE Graduatoria e Finanziamento Ministero della Salute Direzione Generale Ricerca Scientifica e Tecnologica

More information

Bando Giovani Ricercatori Alessandro Liberati 2013 NOT ELIGIBLE FOR FUNDING

Bando Giovani Ricercatori Alessandro Liberati 2013 NOT ELIGIBLE FOR FUNDING Programma di ricerca Regione-Università Bando Giovani Ricercatori Alessandro Liberati 2013 NOT ELIGIBLE FOR FUNDING CCOODDIICCEE CCOOGGNNOOMEE NNOOMEE EENNTTEE TTIITTOOLLOO AARREEAA TTEEMAATTIICCAA 00000147

More information

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction

More information

STEM CELL FELLOWSHIP

STEM CELL FELLOWSHIP Module I: The Basic Principles of Stem Cells 1. Basics of Stem Cells a. Understanding the development of embryonic stem cells i. Embryonic stem cells ii. Embryonic germ cells iii. Differentiated stem cell

More information

Version 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen

Version 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen Version 1 2015 Module guide International Master Program Cardiovascular Science University of Göttingen Part 1 Theoretical modules Synopsis The Master program Cardiovascular Science contains four theoretical

More information

A Genetic Analysis of Rheumatoid Arthritis

A Genetic Analysis of Rheumatoid Arthritis A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.

More information

The Types of stem cells: Totipotent Pluripotent Multipotent

The Types of stem cells: Totipotent Pluripotent Multipotent Stem Cells is the main material for building and regeneration of the body Stem cells are not differentiated and can transform to any cell of organism Stem cells are capable of indefinite renewal through

More information

Stem Cell Quick Guide: Stem Cell Basics

Stem Cell Quick Guide: Stem Cell Basics Stem Cell Quick Guide: Stem Cell Basics What is a Stem Cell? Stem cells are the starting point from which the rest of the body grows. The adult human body is made up of hundreds of millions of different

More information

JUMISC JUMISC. For further information visit our website:

JUMISC JUMISC. For further information visit our website: STEM CELL THERAPY COMPANY PROFILE & SCIENTIFIC ACTIVITIES For further information visit our website: WWW.CCMIJESUSUSON.COM 20 14 JUMISC JUMISC Carretera N-521, km. 41,8 10071 CÁCERES (SPAIN) Tel. (+34)

More information

Project ideas of University of Udine for Horizon 2020 Health 2014/2015 www.uniud.it

Project ideas of University of Udine for Horizon 2020 Health 2014/2015 www.uniud.it Project ideas of University of Udine for Horizon 2020 Health 2014/2015 www.uniud.it The University of Udine is an Italian Public University founded in 1978 by National Law No. August 8, 1977 546, art.

More information

Your Guide to Express Critical Illness Insurance Definitions

Your Guide to Express Critical Illness Insurance Definitions Your Guide to Express Critical Illness Insurance Definitions Your Guide to EXPRESS Critical Illness Insurance Definitions This guide to critical illness definitions will help you understand the illnesses

More information

Co-pay assistance organizations offering assistance

Co-pay assistance organizations offering assistance Acromegaly Acute Exacerbations of Multiple Sclerosis Acute Porphyrias Advanced Idiopathic Parkinson' s Disease Age-Related Macular Degeneration www.theassistancefund.org Alcohol Dependence Alpha-1 Antitrypsin

More information

Stem Cell Transplantation

Stem Cell Transplantation Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance

More information

Medical Surgical Nursing (Elsevier)

Medical Surgical Nursing (Elsevier) 1 of 6 I. The Musculoskeletal System Medical Surgical Nursing (Elsevier) 1. Med/Surg: Musculoskeletal System: The Comprehensive Health History 2. Med/Surg: Musculoskeletal System: A Nursing Approach to

More information

Ministero della Salute

Ministero della Salute Ministero della Salute Direzione Generale della Ricerca e dell' Innovazione in Sanità BANDO 2013 PROGRAMMI DI RETE FINANZIATI PROGRAMMA NETWORK CODICE: 02356160 SCORE MEDIO DEL NETWORK: 13,75 Pediatric

More information

your complete stem cell bank

your complete stem cell bank your complete stem cell bank HYDERABAD - 88985 000 888, WARANGAL - 8297 256 777 VISAKHAPATNAM - 7799 990 774 VIJAYAWADA AND GUNTUR - 7799 990 771 NELLORE - 7799 990 772, KADAPA - 8297 256 700 RAJAHMUNDRY

More information

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine January 27, 2009 Dear Professors (representative) of departments, Subject:

More information

Clinical guidance for MRI referral

Clinical guidance for MRI referral MRI for cervical radiculopathy Referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of spine for a patient 16 years or older for suspected: cervical radiculopathy

More information

Future Oncology: Technology, Products, Market and Service Opportunities

Future Oncology: Technology, Products, Market and Service Opportunities Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter

More information

Demystifying Stem Cells. Brent Bost M.D., CPA, MBA, FACOG

Demystifying Stem Cells. Brent Bost M.D., CPA, MBA, FACOG Demystifying Stem Cells Brent Bost M.D., CPA, MBA, FACOG Disclaimers Author currently serves on Board of Directors of CordTrack Most applications discussed today are not currently FDA approved and are,

More information

Enjoy a position of vantage, come what may.

Enjoy a position of vantage, come what may. Enjoy a position of vantage, come what may. prucrisis covervantage While you have achieved much in life and you and your family enjoy the benefits of success, there may be times when the unexpected happens.

More information

The Lewin Group undertook the following steps to identify the guidelines relevant to the 11 targeted procedures:

The Lewin Group undertook the following steps to identify the guidelines relevant to the 11 targeted procedures: Guidelines The following is a list of proposed medical specialty guidelines that have been found for the 11 targeted procedures to be included in the Medicare Imaging Demonstration. The list includes only

More information

OMA Group Critical Illness Insurance - Covered condition definitions

OMA Group Critical Illness Insurance - Covered condition definitions OMA Group Critical Illness Insurance - Covered condition definitions The term diagnosis shall mean the diagnosis of a covered condition by a licensed physician (other than the insured, the insured s relative

More information

BIOBANKING a challenge for public / private partnerships. Christian Bréchot

BIOBANKING a challenge for public / private partnerships. Christian Bréchot BIOBANKING a challenge for public / private partnerships Christian Bréchot Patient Disease Diagnosis Targeted Personalized therapies Risk medecine prediction Biomarker Diagnostic Theranostic: Efficay Toxicity

More information

2nd MuscleTech Network Workshop. From translational Research to translational Medicine. CONCLUSIONS AND CLOSING REMARKS Dr.

2nd MuscleTech Network Workshop. From translational Research to translational Medicine. CONCLUSIONS AND CLOSING REMARKS Dr. 2nd MuscleTech Network Workshop. From translational Research to translational Medicine. CONCLUSIONS AND CLOSING REMARKS Dr. Carles Pedret MUSCLE AND TENDON WORKSHOP HEALTH AND GENERAL POPULATION SPORTS

More information

Your health is an asset. Don t let critical illness turn it into a liability.

Your health is an asset. Don t let critical illness turn it into a liability. Your health is an asset. Don t let critical illness turn it into a liability. 100% lump sum payout for critical illness1 including early stage My Early Critical Illness Plan Be financially prepared for

More information

Asteron Life Business Insurance

Asteron Life Business Insurance Asteron Life Business Insurance What lump sum covers are available with Asteron Life Business Insurance? Life Cover Life Cover pays a lump sum of money if you pass away or become terminally ill. Total

More information

List of Qualifying Conditions

List of Qualifying Conditions List of Qualifying Conditions Cancer Conditions 1) Adrenal cancer 2) Bladder cancer 3) Bone cancer all forms 4) Brain cancer 5) Breast cancer 6) Cervical cancer 7) Colon cancer 8) Colorectal cancer 9)

More information

We understand you want support right from the beginning

We understand you want support right from the beginning PROTECT We understand you want support right from the beginning PRUearly stage crisis cover Should an illness strike, the earlier it is diagnosed, the easier it is to manage and the higher the chances

More information

IKHLASlink Comprehensive Critical Illness Benefit Secure Takaful Rider

IKHLASlink Comprehensive Critical Illness Benefit Secure Takaful Rider IKHLASlink Comprehensive Critical Illness Benefit Secure Takaful Rider 1. IKHLASlink Comprehensive Critical Illness Benefit Secure Takaful Rider Securing life uncertainties. With IKHLASlink Comprehensive

More information

ERA-Net COFUND Research Programmes on Rare Diseases (E-RARE)

ERA-Net COFUND Research Programmes on Rare Diseases (E-RARE) Bologna 15 Dicembre 2014 ERA-Net COFUND Research Programmes on Rare Diseases (E-RARE) The Role of RER-ASSR Antonio Addis Research Governance Area Agenzia Sanitaria e Sociale Regionale How do Regions might

More information

Progressive Care Insurance for life A NEW TYPE OF INSURANCE

Progressive Care Insurance for life A NEW TYPE OF INSURANCE Progressive Care Insurance for life A NEW TYPE OF INSURANCE New Progressive Care from Sovereign Progressive Care is a type of insurance that is new to New Zealand. It s not a traditional all-or-nothing

More information

1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT

1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT 1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT Learning that your pet has a diagnosis of cancer can be overwhelming. We realize that your pet

More information

Cord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD

Cord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD Cord Blood Banking Scott N. Furlan, MD Ellen S.Plummer, MD Overview Background Biology of Stem Cell Transplant Opportunities i at Parkland Logistics of Banking Potential Barriers Indications for HCT Cancer

More information

Elenco dei periodici elettronici in Ovid Full text

Elenco dei periodici elettronici in Ovid Full text Academic Medicine Addictive Disorders & Their Treatment Advances in Anatomic Pathology Age & Ageing AIDS AIDS Patient Care & Stds AJN, American Journal of Nursing Alzheimer Disease & Associated Disorders

More information

Autoimmunity and immunemediated. FOCiS. Lecture outline

Autoimmunity and immunemediated. FOCiS. Lecture outline 1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic

More information

Opportunities for advancing biomarkers for patient stratification and early diagnosis in liver disease

Opportunities for advancing biomarkers for patient stratification and early diagnosis in liver disease Opportunities for advancing biomarkers for patient stratification and early diagnosis in liver disease 80 Liver Disease and Obesity Liver disease biomarkers: Percent of adult population (United States)

More information

Closed Sub-TOI: L08.000 Life - Other Co Tr Num: BANRD-01 State Status: Approved-Closed

Closed Sub-TOI: L08.000 Life - Other Co Tr Num: BANRD-01 State Status: Approved-Closed Project Name/Number: / 01 Filing at a Glance Company: Banner Life Insurance Company SERFF Tr Num: FNBL-126416557 State: Arkansas TOI: L08 Life - Other SERFF Status: Closed-Approved- State Tr Num: 44441

More information

5 Frequently Asked Questions About Adult Stem Cell Research

5 Frequently Asked Questions About Adult Stem Cell Research 5 Frequently Asked Questions About Adult Stem Cell Research Stem cells are often referred to in the sociopolitical realm with some level of controversy and beyond that, some level of confusion. Many researchers

More information

If you were diagnosed with cancer today, what would your chances of survival be?

If you were diagnosed with cancer today, what would your chances of survival be? Q.1 If you were diagnosed with cancer today, what would your chances of survival be? Ongoing medical research from the last two decades has seen the cancer survival rate increase by more than 40%. However

More information

Chapter 6 Musculoskeletal System Diseases and Disorders

Chapter 6 Musculoskeletal System Diseases and Disorders Chapter 6 Musculoskeletal System Diseases and Disorders Anatomy and Physiology Bones and Joints Bones provide framework and support; classified by shape and composition Joints: where two or more bones

More information

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1 1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

STEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA

STEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA STEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA OVO CLINIC I 8000 BLVD DECARIE, MONTREAL QC H4P 2S4 I 514.798.2000 I OVOCLINIC.COM 2 a therapeutic revolution As the

More information

Limited Pay Policy (L-222B) - Underwriting Guidelines

Limited Pay Policy (L-222B) - Underwriting Guidelines Limited Pay Policy (L-222B) - Underwriting Guidelines 1 Addiction/Abuser Drug - Past or Present Presently Recovered - AA for last 2 years 2 Aids 3 Alcoholic Presently Recovered - AA for last 2 years 4

More information

It s not something you want to think about, but it s something you want to prepare for.

It s not something you want to think about, but it s something you want to prepare for. It s not something you want to think about, but it s something you want to prepare for. StemCyte cord blood banking offers your family a new lifesaving treatment alternative Why Bank Take the once-in-alifetime

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections

More information

Asteron Life Personal Insurance

Asteron Life Personal Insurance Asteron Life Personal Insurance What lump sum covers are available with Asteron Life Personal Insurance? Life Cover Life Cover insurance pays a lump sum of money if you pass away or become terminally ill.

More information

Healthcare services requiring prior authorisation

Healthcare services requiring prior authorisation Annex 2 Healthcare requiring prior authorisation This list does not include organ transplants and does also not apply to long-term care and the primary purpose of which is to support people in need of

More information

Group 2: Critical Illness Benefits

Group 2: Critical Illness Benefits Group 2: Zurich s cover is designed to free yourself and your loved ones from the potentially devastating financial impact that follows diagnosis with a critical illness. 1. Level Term Life or Earlier

More information

ACUTE MYELOID LEUKEMIA (AML),

ACUTE MYELOID LEUKEMIA (AML), 1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly

More information

SUPPLEMENTARY NOTES. Personal General Insurance (4 th Edition) Date Of Issue: 1 October 2014

SUPPLEMENTARY NOTES. Personal General Insurance (4 th Edition) Date Of Issue: 1 October 2014 SUPPLEMENTARY NOTES Personal General Insurance (4 th Edition) Date Of Issue: 1 October 2014 The following amendments have NOT been incorporated in the Study Guide. They should be marked up in the Study

More information

Early Critical Care. confident

Early Critical Care. confident Early Critical Care confident It is important to detect a critical illness early, that is when you have the best chance of a recovery. Medical and technological advancement has now made it possible to

More information

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15 Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microwave_tumor_ablation 12/2011 11/2015 11/2016 11/2015 Description of Procedure or Service Microwave ablation

More information

RITMIR024 - STEM CELL RESEARCH IN CARDIOLOGY

RITMIR024 - STEM CELL RESEARCH IN CARDIOLOGY 1. SCOPE AND METHODOLOGY 2. REPORT SYNOPSIS 2.1 General Definitions Myoblasts Pluripotent Cells Multipotent Cells Progenitor Cells Role of Stem Cells in Repairing the Heart Stem Cell Therapy Stem Cells

More information

Virginia Group Health Insurance Medical History Form

Virginia Group Health Insurance Medical History Form Section 1: To Be Completed by Employer EMPLOYER GROUP NAME REQUESTED EFFECTIVE DATE Section 2: Employee Information Employee Name: Employee Address: (street, city, state & zip) Name of Current Insurer/HMO:

More information

CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.

CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc. Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs

More information

Critical PROVIDER FIELD UNDERWRITING GUIDE & RATE BOOK

Critical PROVIDER FIELD UNDERWRITING GUIDE & RATE BOOK G T L Critical PROVIDER FIELD UNDERWRITING GUIDE & RATE BOOK 10 OR 20 YEAR RENEWABLE TERM LIFE INSURANCE WITH A CRITICAL ILLNESS ACCELERATED BENEFIT RIDER WHICH PROVIDES CASH BENEFITS FOR 18 CRITICAL CONDITIONS

More information

Term Critical Illness Insurance

Term Critical Illness Insurance Term Critical Illness Insurance PRODUCT GUIDE 5368-01A-JUL14 ASSUMPTION LIFE This document is a summary of the various features of Assumption Life's products. It is neither a contract nor an insurance

More information

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014 ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the

More information

CRITICAL ILLNESS BENEFIT PLAN

CRITICAL ILLNESS BENEFIT PLAN Insured by ACE INA Life Insurance Note to employees/plan members with existing group benefit plans through RWAM: To confirm whether or not you are insured under this Critical Illness Benefit Plan and your

More information

Malignant Lymphomas and Plasma Cell Myeloma

Malignant Lymphomas and Plasma Cell Myeloma Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations

More information

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research infoaging guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research WHAT ARE STEM CELLS? Stem cells are cells that, in cell cultures

More information

Cancer is the leading cause of death for Canadians aged 35 to 64 and is also the leading cause of critical illness claims in Canada.

Cancer is the leading cause of death for Canadians aged 35 to 64 and is also the leading cause of critical illness claims in Canada. Underwriting cancer In this issue of the Decision, we provide an overview of Canadian cancer statistics and the information we use to make an underwriting decision. The next few issues will deal with specific

More information

A m e r i C A n A C A d e m y o f A N T I - A G i n G M e d i c i n e

A m e r i C A n A C A d e m y o f A N T I - A G i n G M e d i c i n e VOLUME II A m e r i C A n A C A d e m y o f A N T I - A G i n G M e d i c i n e Established in 1992 www.worldhealth.net Fellowship in Integrative Cancer Therapy The American Academy of Anti-aging Medicine

More information

AN UNEXPECTED ILLNESS BRINGS UNEXPECTED CHALLENGES

AN UNEXPECTED ILLNESS BRINGS UNEXPECTED CHALLENGES Group Critical Illness Insurance AN UNEXPECTED ILLNESS BRINGS UNEXPECTED CHALLENGES Your employees matter. Help them plan accordingly. WHAT IF THEY COULDN T CARRY THE LOAD? Your employees can t afford

More information

Medical Services Protocol Updates

Medical Services Protocol Updates Protocol Medical Services Protocol Updates Distribution Date: June 1, 2010 The following clinical protocol update includes information on protocols that have had an annual review recently resulting in

More information

Oncology. Objectives. Cancer Nomenclature. Cancer is a disease of the cell Cancer develops when certain cells begin to grow out of control

Oncology. Objectives. Cancer Nomenclature. Cancer is a disease of the cell Cancer develops when certain cells begin to grow out of control Oncology Objectives Describe the etiology and pathophysiological mechanisms of cancer Discuss medical and family history findings relevant to cancer Identify general signs and symptoms associated with

More information

Liver Cancer And Tumours

Liver Cancer And Tumours Liver Cancer And Tumours What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood from all parts of the body, cancer cells from elsewhere can

More information

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational

More information

AMERICAN HERITAGE LIFE INSURANCE COMPANY (AHL) 1776 AMERICAN HERITAGE LIFE DRIVE JACKSONVILLE, FLORIDA 32224

AMERICAN HERITAGE LIFE INSURANCE COMPANY (AHL) 1776 AMERICAN HERITAGE LIFE DRIVE JACKSONVILLE, FLORIDA 32224 AMERICAN HERITAGE LIFE INSURANCE COMPANY (AHL) 1776 AMERICAN HERITAGE LIFE DRIVE JACKSONVILLE, FLORIDA 32224 For AHL Home Office use only tes EVIDENCE OF INSURABILITY AND ENROLLMENT FORM Check appropriate

More information

VOLUNTARY GROUP CRITICAL ILLNESS INSURANCE DEFINITIONS

VOLUNTARY GROUP CRITICAL ILLNESS INSURANCE DEFINITIONS VOLUNTARY GROUP CRITICAL ILLNESS INSURANCE DEFINITIONS This document is designed to outline some of the definitions under specific Critical Illness Group Polices issued by Industrial Alliance Insurance

More information

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative

More information

Management in the pre-hospital setting

Management in the pre-hospital setting Management in the pre-hospital setting Inflammation of the joints Two main types: Osteoarthritis - cartilage loss from wear and tear Rheumatoid arthritis - autoimmune disorder Affects all age groups,

More information

GRANIX (tbo-filgrastim)

GRANIX (tbo-filgrastim) RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil

More information

THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS

THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS Ushering in a new era of cancer medicine Center is ushering in a new era of cancer medicine. Progress that could not even be imagined a decade ago is now being realized in our laboratories and our clinics.

More information

Background Information

Background Information Background Information 1. What are stem cells? 2. What might stem cell research achieve? 3. Why we need to continue research using embryonic stem cells? 4. Time taken for discoveries 5. Examples of stem

More information

NOVEL PLATFORMS FOR CANCER DIAGNOSIS

NOVEL PLATFORMS FOR CANCER DIAGNOSIS NOVEL PLATFORMS FOR CANCER DIAGNOSIS Luca Beneduce, Ph.D. Founded in 2001 and headquartered in Venice (Italy) Xeptagen is a privately held biotech company funded by venture capital. Xeptagen s mission

More information

LIVER CANCER AND TUMOURS

LIVER CANCER AND TUMOURS LIVER CANCER AND TUMOURS LIVER CANCER AND TUMOURS Healthy Liver Cirrhotic Liver Tumour What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood

More information

Adirondack Community Physicians Specialty Groups

Adirondack Community Physicians Specialty Groups Adirondack Community Physicians Specialty Groups Orthopedic Group 1903 Sunset Avenue Phone: 315.624.8150 Margaret R. Albanese, MD Dr. Albanese is board certified by the American Board of Orthopaedic Surgery

More information

INTERNATIONAL COURSE:

INTERNATIONAL COURSE: INTERNATIONAL COURSE: Novel mechanisms of signal transduction involved in cancer chemoresistance - Focus on IGF signaling integration and cross-talk. University Campus S Venuta - Catanzaro, Italy Lecture

More information

6/3/2011. High Prevalence and Incidence. Low back pain is 5 th most common reason for all physician office visits in the U.S.

6/3/2011. High Prevalence and Incidence. Low back pain is 5 th most common reason for all physician office visits in the U.S. High Prevalence and Incidence Prevalence 85% of Americans will experience low back pain at some time in their life. Incidence 5% annual Timothy C. Shen, M.D. Physical Medicine and Rehabilitation Sub-specialty

More information

A Focus on Multiple Myeloma

A Focus on Multiple Myeloma A Focus on Multiple Myeloma Guest Expert: Madhav Dhodapkar, MD Professor of Hematology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed and Dr.

More information

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae Ariela Benigni Biol.Sci.D., Ph.D. Curriculum Vitae Personal Data Name: Date and place of birth: Citizenship: E-mail: Ariela Benigni December 16, 1955 - Bergamo, Italy Italian ariela.benigni@marionegri.it

More information

CRITICAL ILLNESS PROGRAM

CRITICAL ILLNESS PROGRAM CRITICAL ILLNESS PROGRAM For the Employees of: Students Association of Bow Valley College Policy Number: CI10372102 Underwritten by: ACE INA Life Insurance Effective Date: September 1, 2014 This brochure

More information

SUPER CARE CRITICAL ILLNESS PROTECTOR

SUPER CARE CRITICAL ILLNESS PROTECTOR SUPER CARE CRITICAL ILLNESS PROTECTOR At ACE Life, we are committed to helping our valued customers achieve financial security and have a peace of mind through our comprehensive range of life insurance

More information

Enhancements to OneCare Product updates

Enhancements to OneCare Product updates Enhancements to Product updates INSURANCE September 2013 Your policy is now even better. Here s what the upgrades mean for you. Your policy includes a guarantee of upgrade. That means that when we improve

More information

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes

More information

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart

More information

Birth Date: Sex: Home Phone Number:

Birth Date: Sex: Home Phone Number: A 35674 To apply for AmeriHealth Medigap Plans... Please reference the enclosed AmeriHealth Medigap Plans Outline of Coverage for the monthly premium based on your plan. Check the ONE plan for which you

More information

Unit 1 Higher Human Biology Summary Notes

Unit 1 Higher Human Biology Summary Notes Unit 1 Higher Human Biology Summary Notes a. Cells tissues organs body systems Division of labour occurs in multicellular organisms (rather than each cell carrying out every function) Most cells become

More information

Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology

Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology INTRODUCTION 2009 A university wishing to have an accredited program in Pediatric Hematology/Oncology must also

More information

$20 million. $3,000,000 Jennifer Goodman Linn Laboratory of New Drug Development in Sarcoma and Rare Cancers $1,000,000 $1,000,000

$20 million. $3,000,000 Jennifer Goodman Linn Laboratory of New Drug Development in Sarcoma and Rare Cancers $1,000,000 $1,000,000 Our 2014 Impact Funding Allocations Cycle for Survival funds promise: Our donations launch and accelerate research studies and clinical trials that drive discovery. By helping fill the funding gap in rare

More information

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used? Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or

More information

Facts about Zurich Claims. Zurich Life Risk

Facts about Zurich Claims. Zurich Life Risk Facts about Zurich Claims Zurich Life Risk A closer look at the claims Income Protection claims sample extract started Cause Occupation Duration (days) Initial monthly benefit Benefits paid to date 23

More information

North Carolina Rheumatology Association Position Statements

North Carolina Rheumatology Association Position Statements North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.

More information

Roche Position on Human Stem Cells

Roche Position on Human Stem Cells Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with

More information